CUSIP 501147102 · who reports it, how much, and how much it matters to them
21 of the 720 hedge fund managers we track reported shares of Krystal Biotech, Inc. (Nasdaq: KRYS) on Form 13F for 30 June 2026. Between them they reported USD 1.5bn. The largest position belongs to Avoro Capital Advisors, at USD 1.1bn. The manager with the most riding on it is Redmile Group, where it is 15.8% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Avoro Capital Advisors1 fund on PPLI.com | USD 1.1bn | 9.6% |
| 2 | Redmile Group10 funds on PPLI.com | USD 235m | 15.8% |
| 3 | Braidwell12 funds on PPLI.com | USD 48m | 1.8% |
| 4 | Orbimed Advisors1 fund on PPLI.com | USD 31m | 0.6% |
| 5 | S Squared Technology1 fund on PPLI.com | USD 29m | 8.9% |
| 6 | Renaissance Technologies13 funds on PPLI.com | USD 22m | 0.0% |
| 7 | Bridgewater Associates45 funds on PPLI.com | USD 20m | 0.1% |
| 8 | Cinctive Capital Management5 funds on PPLI.com | USD 6.1m | 0.2% |
| 9 | Two Sigma Investments35 funds on PPLI.com | USD 2.3m | 0.0% |
| 10 | Atika Capital Management3 funds on PPLI.com | USD 2.2m | 0.1% |
| 11 | HighVista Strategies27 funds on PPLI.com | USD 1.2m | 0.3% |
| 12 | Citadel Advisors32 funds on PPLI.com | USD 1m | 0.0% |
| 13 | Freestone Grove Partners1 fund on PPLI.com | USD 342,000 | 0.0% |
| 14 | CIBC Asset Management69 funds on PPLI.com | USD 330,000 | 0.0% |
| 15 | Diametric Capital2 funds on PPLI.com | USD 308,000 | 0.0% |
| 16 | Bayforest Capital1 fund on PPLI.com | USD 39,397 | 0.0% |
| 17 | Persistent Asset Partners10 funds on PPLI.com | USD 18,212 | 0.0% |
| 18 | Fulcrum Asset Management LLP7 funds on PPLI.com | USD 10,588 | 0.0% |
| 19 | Walleye Capital8 funds on PPLI.com | USD 4,460 | 0.0% |
| 20 | The Quarry1 fund on PPLI.com | USD 1,115 | 0.0% |
| 21 | Summit Global Investments1 fund on PPLI.com | USD 805 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Redmile Group | USD 235m | 15.8% |
| 2 | Avoro Capital Advisors | USD 1.1bn | 9.6% |
| 3 | S Squared Technology | USD 29m | 8.9% |
| 4 | Braidwell | USD 48m | 1.8% |
| 5 | Orbimed Advisors | USD 31m | 0.6% |
| 6 | HighVista Strategies | USD 1.2m | 0.3% |
| 7 | Cinctive Capital Management | USD 6.1m | 0.2% |
| 8 | Atika Capital Management | USD 2.2m | 0.1% |
| 9 | Bridgewater Associates | USD 20m | 0.1% |
| 10 | Summit Global Investments | USD 805 | 0.0% |
Krystal Biotech, Inc. trades under the symbol KRYS on the Nasdaq. Its CUSIP, the code used on Form 13F, is 501147102.
21 of the 720 hedge fund managers PPLI.com tracks reported Krystal Biotech, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Avoro Capital Advisors (USD 1.1bn), Redmile Group (USD 235m), Braidwell (USD 48m), Orbimed Advisors (USD 31m) and S Squared Technology (USD 29m).
21 managers in our coverage reported it, and between them they run 285 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Redmile Group, where the position was 15.8% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Krystal Biotech, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.